Drugs / Diammonium glycyrrhizinate
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07616271 | May 2026 → May 2029 expected | aggressive B-cell non-Hodgkin lymphoma | Tongji Hospital | Not yet recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT03349008 | Nov 2017 → Dec 2019 | chronic hepatitis B virus infection | Cttq | Unknown | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 2 | NCT05023915 Comparator | Aug 2021 overdue | autoimmune thrombocytopenia | Shandong University | Active not recruiting | No outcome recorded |
| Phase 3 | NCT01342185 Comparator | Mar 2010 → Jul 2013 | chronic hepatitis B virus infection | Nanfang Hospital, Southern Medical University | Unknown | No outcome recorded |
| — | NCT01643447 Comparator | May 2012 → Dec 2014 | hepatocellular carcinoma | Eastern Hepatobiliary Surgery Hospital | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Diammonium glycyrrhizinate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01342185 ↗ |
| Known as | Diammonium glycyrrhizate | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297742 ↗ |
| Route | Oral | “receive oral Diammonium glycyrrhizinate Capsules 150mg, three times a day for 12 weeks.” NCT01342185 ↗ |